SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Nearly 22 percent more physician specialty practices employed nurse practitioners or physician assistants in 2016 than they did in 2008, according to a research letter published April 30 in JAMA Internal Medicine.

Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.

The American Heart Association (AHA)/American Stroke Association (ASA) is revisiting its recently updated stroke guidelines after issuing a “correction” that removed several portions.

A new nationwide study from Japan highlighted the importance of timely ambulance arrival, showing that bystander defibrillation and cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest are essentially worthless if EMS response times are slower than 13 minutes and 11 minutes, respectively.

Common therapies used in the treatment of psoriasis may help reduce coronary plaque, according to a new study presented April 26 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions in San Diego.

Alteplase is sometimes administered to dissolve clots before endovascular thrombectomy in patients with ischemic stroke. But a new study in the New England Journal of Medicine demonstrates tenecteplase, a genetically modified form of alteplase, is associated with better blood flow restoration and improved functional outcomes.

New research suggests people exhibiting ST-segment elevation myocardial infarction (STEMI) receive life-saving treatment more quickly if they live in states that allow emergency medical services (EMS) to take patients straight to hospitals that offer specialized treatment, rather than those that do not.

An imaging technology called RAPID CTA that enables 3D visualization of a brain’s blood vessels has received FDA clearance, iSchemaView announced May 1.

A new device allows clinicians to remove blood clots from the pulmonary arteries and improve right ventricular function without the use of thrombolytics, according to a late-breaking clinical study presented April 26 at SCAI 2018 in San Diego.